Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mavacamten · Camzyos

Small molecule · Inhibitor of cardiac myosin (MYH7) · developed by Bristol

Approved FDA, Apr 2022

BMY Developer

1 Registered trials

What is Mavacamten?

Mavacamten is an allosteric and reversible inhibitor of cardiac myosin that modulates myosin heads entering power-generating states, reducing force-producing cross-bridge formation. It shifts myosin toward an energy-sparing, super-relaxed state. In hypertrophic cardiomyopathy patients, mavacamten reduces dynamic left ventricular outflow tract obstruction and improves cardiac filling pressures.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Camzyos
Drug type: Small molecule
Targets: cardiac myosin (MYH7)
Mechanism: Inhibitor of cardiac myosin (MYH7)
Pathways: myosin-actin cross-bridge formation, super-relaxed state
Therapy area: Cardiovascular
Developer: Bristol (BMY)
FDA status: Approved as Camzyos (April 28, 2022), NDA214998 · FDA label
UNII: 49VRS39N4U

✅ FDA-approved uses

Obstructive hypertrophic cardiomyopathy

From the indications section of the FDA label (version of Apr 17, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06372457	N/A	Hypertrophic Cardiomyopathy (HCM)	Active not recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertrophic Cardiomyopathy (HCM)

Other drugs acting on MYH7

Aficamten FDA approved

More from Bristol

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Mavacamten

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z